Financial Performance - The company's operating revenue for the first half of 2021 was CNY 454,884,074.49, representing a 14.61% increase compared to CNY 396,894,638.67 in the same period last year[23]. - The net profit attributable to shareholders was CNY 41,371,047.86, which is a 25.96% increase from CNY 32,843,900.69 year-on-year[23]. - The net cash flow from operating activities surged by 202.94% to CNY 120,294,568.26, compared to CNY 39,709,022.32 in the previous year[23]. - The basic earnings per share increased by 26.01% to CNY 0.1250, up from CNY 0.0992 in the same period last year[23]. - The net profit after deducting non-recurring gains and losses was 35,876,286.87 yuan, reflecting a growth of 28.67% year-on-year[31]. - The company reported a net profit for the first half of 2021 of CNY 49,200,027.29, representing a 26.2% increase from CNY 38,978,093.40 in the first half of 2020[133]. - The total comprehensive income for the first half of 2021 was CNY 73,941,591.99, showing a significant increase compared to the previous period[152]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,690,379,182.94, a decrease of 3.78% from CNY 2,796,099,005.75 at the end of the previous year[23]. - Total liabilities decreased to CNY 547,590,841.81 from CNY 663,864,893.91, a reduction of 17.5%[125]. - Current liabilities totaled CNY 428,116,650.79, down 25.5% from CNY 574,522,426.34[125]. - The equity attributable to shareholders increased to CNY 2,027,160,437.49 from CNY 1,995,717,937.63, an increase of 1.8%[126]. - The total liabilities and equity at the end of the current period amount to 2,080,200,000, consistent with the company's financial structure[150]. Revenue Breakdown - The pharmaceutical sector generated ¥333,043,864.57, accounting for 73.21% of total revenue, with a year-on-year growth of 7.96%[46]. - Revenue from the health food sector surged by 93.39% to ¥44,378,842.73, primarily driven by increased sales of ginseng products[48]. - The cosmetics sector reported revenue of ¥74,717,896.59, reflecting an 18.73% increase from the previous year[46]. - Capsule products contributed ¥215,621,692.51, making up 47.40% of total revenue, with a growth of 7.66% year-on-year[47]. Research and Development - The company has developed a complete ginseng industry chain, expanding from pharmaceutical products to health foods and cosmetics[32]. - The company has registered over 500 cosmetic products, leveraging its ginseng resources and technology[35]. - The company reported a significant increase in R&D investment, which increased by 38.13% to CNY 21,152,443.12, primarily due to higher clinical trial costs[43]. - The company has published 206 academic papers, including 21 indexed by SCI and 42 RCT clinical trial papers, highlighting its commitment to research[36]. Operational Risks - The company faced various operational risks, which are detailed in the report, and it is advised that investors pay attention to these risks[6]. - The company faces risks related to industry policy adjustments, including increased regulatory scrutiny and changes in drug approval processes[58]. - The company faces risks of rising production costs due to increased prices of raw materials, labor, and logistics[60]. - There is a risk of drug price declines as a result of stricter healthcare cost control measures and policies affecting drug pricing mechanisms[60]. Corporate Governance and Social Responsibility - The company emphasizes the protection of shareholder and creditor rights through improved governance and timely information disclosure[72]. - The company actively participates in social responsibility initiatives, contributing to community development and environmental sustainability[72]. - The company has been recognized as a "Contract-abiding and Trustworthy Enterprise" for several consecutive years by the Administration for Industry and Commerce[73]. - The company prioritizes employee rights and well-being, providing social insurance and opportunities for professional development[72]. Shareholder Information - The total number of shares remained unchanged at 330,951,600, with a slight decrease in restricted shares from 99,231,016 to 98,676,111[102]. - Zhang Yisheng holds 39.08% of the shares, totaling 129,348,530 shares, with no changes during the reporting period[107]. - Liu Jianming's shareholding decreased by 40,000 shares, holding 12,831,403 shares, representing 3.88%[107]. - The company has not conducted any repurchase transactions among the top 10 shareholders during the reporting period[108]. Environmental Compliance - The company has established a comprehensive environmental management system and emergency response plan to handle potential environmental incidents[70]. - The company has not faced any administrative penalties for environmental issues during the reporting period, indicating compliance with environmental regulations[69]. - The company actively invested in environmental protection and energy conservation, adhering to relevant environmental regulations for waste management[73]. Accounting and Financial Reporting - The financial statements are prepared based on the accrual basis of accounting, in accordance with the relevant accounting standards[160]. - The company uses RMB as its functional currency for accounting purposes[166]. - The financial report complies with the requirements of the accounting standards, reflecting the group's financial position and operating results accurately[163]. - The company recognizes foreign currency cash flows using the spot exchange rate on the transaction date, with adjustments for exchange rate fluctuations reported separately in the cash flow statement[179].

Financial Performance - The company's operating revenue for Q1 2021 was ¥229,097,736.43, representing a 14.31% increase compared to ¥200,410,031.97 in the same period last year[8]. - Net profit attributable to shareholders for Q1 2021 was ¥27,765,054.54, up 29.24% from ¥21,483,641.33 in the previous year[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥23,405,772.17, reflecting a 40.73% increase from ¥16,632,110.71 year-on-year[8]. - The basic earnings per share for Q1 2021 was ¥0.0839, a 29.28% increase from ¥0.0649 in the same period last year[8]. - The company achieved operating revenue of CNY 229,097,736.43, a year-on-year increase of 14.31%[18]. - Net profit attributable to shareholders reached CNY 27,765,054.54, up 29.24% compared to the same period last year[18]. - The total profit for the first quarter was CNY 39,024,730.06, an increase from CNY 29,813,960.90 year-over-year[42]. - The company reported a significant increase in operating profit, which was CNY 41,911,932.69, compared to CNY 31,513,381.89 in the previous year[42]. - Net profit for Q1 2021 increased to CNY 34,668,779.18, compared to CNY 26,187,829.40 in the same period last year[40]. - The total comprehensive income for the first quarter was CNY 33,186,719.33, compared to CNY 25,202,056.45 in the same period last year[42]. Cash Flow - The net cash flow from operating activities was ¥29,363,113.24, a decrease of 7.44% compared to ¥31,724,684.07 in the previous year[8]. - Cash flow from tax refunds increased by 63.62% to CNY 309,038.42, due to higher VAT refunds received[18]. - Total cash inflow from operating activities was ¥245,212,053.73, up from ¥236,143,130.92 in the previous year, reflecting a growth of 4.5%[49]. - Cash outflow from operating activities totaled ¥215,848,940.49, compared to ¥204,418,446.85 in the same period last year, indicating an increase of 5.5%[49]. - The company reported a net cash flow from investing activities of -¥13,880,051.32, worsening from -¥3,085,989.58 in Q1 2020[50]. - Cash inflow from financing activities was ¥50,000,000.00, down from ¥110,000,000.00 in the previous year, representing a decline of 54.5%[50]. - The net cash flow from financing activities was -¥12,241,385.43, compared to -¥2,899,569.82 in Q1 2020, indicating a significant increase in cash outflow[50]. - The ending balance of cash and cash equivalents was ¥290,238,191.42, an increase from ¥88,753,739.80 at the end of Q1 2020[50]. - The net increase in cash and cash equivalents for the period was ¥3,241,676.49, compared to an increase of ¥25,739,124.67 in Q1 2020[50]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,768,818,814.32, down 0.98% from ¥2,796,099,005.75 at the end of the previous year[8]. - The net assets attributable to shareholders at the end of the reporting period were ¥2,023,482,992.17, an increase of 1.39% from ¥1,995,717,937.63 at the end of the previous year[8]. - Total assets as of March 31, 2021, amounted to CNY 2,809,491,036.17, compared to CNY 2,795,950,343.62 at the end of 2020[36]. - Total liabilities decreased to CNY 804,389,575.74 from CNY 853,772,344.48 at the end of 2020[37]. - The company's equity increased to CNY 2,005,101,460.43 from CNY 1,942,177,999.14 at the end of 2020[37]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,899[12]. - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, totaling 129,348,530 shares[12]. Expenses - Management expenses rose by 24.15% to CNY 24,930,308.88, attributed to increased employee insurance and salary costs[18]. - Financial expenses decreased by 55.55% to CNY 1,314,678.47, mainly due to increased interest from agreement deposits[18]. - Research and development expenses for Q1 2021 were CNY 4,823,806.99, compared to CNY 4,295,439.68 in the previous period[40]. - The company incurred financial expenses of CNY 2,503,292.90, down from CNY 4,483,604.94 in the previous year[44]. - Research and development expenses for the first quarter were CNY 3,643,031.48, compared to CNY 3,472,786.86 in the previous year[44].

Financial Performance - The company's operating revenue for 2020 was ¥842,589,907.04, a decrease of 16.80% compared to ¥1,012,748,483.99 in 2019[18] - The net profit attributable to shareholders for 2020 was ¥80,060,085.80, representing an increase of 4.52% from ¥76,598,736.73 in 2019[18] - The basic earnings per share for 2020 was ¥0.2419, up 4.54% from ¥0.2314 in 2019[18] - The total assets at the end of 2020 were ¥2,796,099,005.75, reflecting a 12.00% increase from ¥2,496,513,671.23 at the end of 2019[18] - The net assets attributable to shareholders at the end of 2020 were ¥1,995,717,937.63, a 3.29% increase from ¥1,932,205,431.83 at the end of 2019[18] - The net cash flow from operating activities for 2020 was ¥203,514,966.83, a decrease of 3.49% from ¥210,871,994.83 in 2019[18] - The company reported a weighted average return on equity of 4.08% for 2020, slightly up from 4.04% in 2019[18] - The net profit after deducting non-recurring gains and losses for 2020 was ¥65,746,181.53, an increase of 3.15% from ¥63,736,372.05 in 2019[18] - The total revenue for 2020 was ¥842,589,907.04, a decrease of 16.80% compared to ¥1,012,748,483.99 in 2019[49] - The pharmaceutical industry generated ¥642,748,349.58, accounting for 76.28% of total revenue, down 11.42% from the previous year[49] - The cosmetics sector saw a significant decline, with revenue of ¥115,960,117.33, representing a 37.88% drop from ¥186,669,072.67 in 2019[49] Dividend Distribution - The company plans to distribute a cash dividend of ¥0.30 per 10 shares, based on a total of 330,951,600 shares[6] - The cash dividend for 2020 represents 12.40% of the net profit attributable to the company's ordinary shareholders, which was ¥80,060,085.80[93] - In 2019, the company distributed a cash dividend of ¥0.50 per share, totaling ¥16,547,580.00, which accounted for 21.60% of the net profit attributable to ordinary shareholders[93] - The company did not distribute any cash dividends for the year 2018 due to the need for significant funding for future investments and operations[91] - The total undistributed profits at the end of the reporting period amounted to ¥669,928,871.12[93] - The company has established a three-year shareholder return plan to ensure a stable dividend policy[89] Market and Industry Position - The company faces risks including industry policy adjustments, rising production costs, and talent shortages, which may impact future performance[6] - The company is positioned in a weak cyclical industry with strong defensive characteristics, showing resilience against macroeconomic fluctuations[35] - The health industry in China is projected to reach a market value of 16 trillion yuan by 2030, indicating significant growth potential for the company[34] - The company has a strong supply chain advantage, integrating upstream and downstream operations in the ginseng industry, enhancing its competitive edge[37] - The company aims to solidify its position as a leading enterprise in the ginseng industry by expanding its product offerings and market reach[82] Research and Development - The company completed clinical studies for new products, including Zhenyuan capsules for diabetes and XinYue capsules for myocardial energy metabolism[62] - Total R&D investment was ¥33,226,923.58, accounting for 3.94% of operating revenue, an increase of 0.43% from the previous year[62] - The company launched 18 new food products and completed certifications for 8 categories of food production licenses during the reporting period[43] - The company has developed 11 types of dosage forms that have obtained national GMP certification, with 117 varieties and 130 drug approval numbers[27] - The company has received 11 national invention patents related to ginseng cultivation techniques[28] - New product development will focus on market-oriented projects, enhancing competitiveness through improved quality and efficacy of existing products[82] Operational Challenges - The cosmetics segment faced significant challenges due to COVID-19, leading to a shift towards online sales channels, including the launch of a new online shopping platform[45] - Sales expenses decreased by 21.45% to ¥402,566,968.04 due to adjustments in marketing policies and the impact of COVID-19 on sales revenue[61] - R&D expenses decreased by 19.31% to ¥15,711,256.37, reflecting a focus on optimizing product pipelines and innovation[61] - The company reported a significant reduction in inventory levels, with a decrease of 41.45% to 3,959,917 boxes compared to the previous year[53] Corporate Governance - The company has established a performance evaluation system linking employee salaries to company performance and individual contributions[160] - The board of directors consists of nine members, including three independent directors, and operates in compliance with relevant laws and regulations[165] - The company maintains a transparent information disclosure system, ensuring timely and accurate communication with all investors[166] - The independent directors attended all board meetings and shareholder meetings, demonstrating their commitment to corporate governance[172] - The company has established a mechanism for evaluating and incentivizing senior management, ensuring accountability and performance alignment[178] Social Responsibility - The company emphasizes employee rights protection and adheres to labor laws, ensuring a harmonious labor relationship and providing various social insurances[122] - The company actively participates in social welfare initiatives, focusing on tax compliance and support for vulnerable groups[123] - The company has been recognized as a "Contract-abiding and Trustworthy Enterprise" by the administration for several consecutive years, reflecting its commitment to social responsibility[123] Financial Management - The company reported a significant increase in intangible assets, which rose to ¥123,411,899.26 in 2020 from ¥54,737,906.41 in 2019, representing an increase of approximately 125%[200] - Cash and cash equivalents surged to ¥286,996,514.93 in 2020, up from ¥63,014,615.13 in 2019, marking an increase of about 355.5%[199] - Short-term borrowings increased to ¥405,402,493.05 in 2020, compared to ¥280,000,000.00 in 2019, reflecting a rise of about 44.8%[200] - The company has established an independent financial department and accounting system, ensuring independent financial decision-making[169] Shareholding Structure - The total number of shares is 330,951,600, with 29.98% being restricted shares and 70.02% being unrestricted shares[131] - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, amounting to 129,348,530 shares[134] - The company has not reported any other shareholders holding more than 10% of shares apart from the identified major shareholders[140] - The company is addressing issues related to shareholding representation and has implemented a plan to reduce the shares held by proxy shareholders[136]

Financial Performance - Operating revenue for the reporting period was ¥217,121,787.36, a decrease of 9.74% year-on-year, while year-to-date revenue was ¥614,016,426.03, down 17.68% compared to the same period last year[9] - Net profit attributable to shareholders for the reporting period was ¥21,344,867.38, an increase of 39.86% year-on-year, with year-to-date net profit at ¥54,188,768.07, a slight decrease of 2.03%[9] - Basic earnings per share for the reporting period were ¥0.0645, up 39.91% year-on-year, with diluted earnings per share also at ¥0.0645[9] - Total operating revenue for the third quarter was CNY 217,121,787.36, a decrease from CNY 240,548,305.91 in the previous period[40] - The total profit for the third quarter was CNY 29,036,243.91, an increase of 55.4% from CNY 18,694,158.23 in the same period last year[42] - The net profit for the third quarter reached CNY 24,811,661.81, representing a 64.4% increase from CNY 15,131,185.24 year-over-year[42] - The company's operating revenue for the third quarter of 2020 was CNY 482.75 million, a decrease of 17% compared to CNY 580.90 million in the same period last year[53] - The net profit attributable to the parent company was CNY 54.19 million, down 2% from CNY 55.31 million year-on-year[51] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,656,227,086.82, an increase of 6.40% compared to the end of the previous year[9] - Total liabilities rose to CNY 551,133,312.55, up from CNY 438,662,072.17, indicating an increase of about 25.6%[34] - Current liabilities totaled CNY 495,421,577.39, compared to CNY 396,009,424.20, marking an increase of approximately 25.1%[34] - Non-current liabilities increased to CNY 55,711,735.16 from CNY 42,652,647.97, representing a growth of about 30.6%[34] - Owner's equity totaled CNY 2,105,093,774.27, up from CNY 2,057,851,599.06, showing an increase of approximately 2.3%[35] - Total assets increased to CNY 2,656,227,086.82 from CNY 2,496,513,671.23, reflecting a growth of approximately 6.4%[35] - Shareholders' equity totaled CNY 2,057,851,599.06, including CNY 330,951,600.00 in share capital and CNY 662,061,469.59 in undistributed profits[67] Cash Flow - The net cash flow from operating activities was ¥41,286,087.37, a significant increase of 391.10% compared to the same period last year, while year-to-date cash flow decreased by 37.04%[9] - Cash flow from operating activities decreased by 37.04% to ¥80,995,109.69 from ¥128,646,977.15, mainly due to reduced cash payments related to operating activities[19] - The net cash flow from operating activities for Q3 2020 was ¥80,995,109.69, a decrease of 37.0% compared to ¥128,646,977.15 in Q3 2019[58] - Total cash inflow from operating activities was ¥698,939,437.12, down 19.6% from ¥869,039,329.29 in the previous year[58] - Cash outflow from operating activities totaled ¥617,944,327.43, a decrease of 16.5% compared to ¥740,392,352.14 in Q3 2019[58] - The net cash flow from investing activities was -¥5,049,230.35, compared to -¥15,296,426.17 in the same period last year, indicating an improvement[59] - Cash inflow from financing activities was ¥485,000,000.00, an increase of 50.4% from ¥322,550,000.00 in Q3 2019[59] - The net cash flow from financing activities was ¥99,539,423.01, compared to -¥90,838,686.33 in the previous year, showing a significant turnaround[59] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,486[13] - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, totaling 129,348,530 shares[13] - The company has not conducted any repurchase transactions among the top 10 shareholders during the reporting period[14] Government Subsidies and Investments - Other income surged by 140.17% to ¥17,864,094.02 from ¥7,438,032.81, primarily due to increased government subsidies received[19] - The company received a total of ¥7,196,800 in government subsidies from January 1 to April 13, 2020, and ¥15,680,700 from April 13 to August 18, 2020[21] - The company plans to invest ¥344,790,000 in the construction of a ginseng deep processing industry project, requiring 223.5 acres of land[21] Expenses - The company reported a significant increase in financial expenses, which decreased by 41.28% to ¥7,715,363.07 from ¥13,139,246.29, due to a reduction in the average balance of short-term borrowings[19] - Research and development expenses decreased to CNY 5,413,750.43, a reduction of 24.6% compared to CNY 7,187,456.00 in the previous year[41] - Sales expenses for the third quarter were CNY 108,494,192.12, down 15.9% from CNY 128,943,551.63 year-over-year[41] - The income tax expense for the quarter was CNY 10.48 million, compared to CNY 12.33 million in the same period last year, reflecting a decrease of about 15%[50] Other Financial Metrics - The weighted average return on net assets was 1.09%, an increase from 0.29% in the previous year[9] - The company reported a credit impairment loss of CNY -496,729.74, significantly improved from CNY -6,292,297.70 in the previous year[41] - The company reported a credit impairment loss of CNY -4.43 million, an improvement from CNY -7.39 million in the previous year[50] - The total comprehensive income for the third quarter was CNY 24,811,661.81, compared to CNY 15,131,185.24 in the same period last year, reflecting a growth of 64.4%[43] - The total comprehensive income for the third quarter was CNY 63.79 million, down from CNY 68.31 million year-on-year[51]

1 证券代码：002566 证券简称：益盛药业 公告编号：2020-029 吉林省集安益盛药业股份有限公司 关于投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，吉林省集安益盛药业股份有限公司（以 下简称"公司"）将参加由吉林证监局、吉林省证券业协会、深圳市全景网络有 限公司共同举办的"提高公司质量 做受尊敬的上市公司--2020年吉林辖区上市 公司投资者网上集体接待日"活动，现将有关事项公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆"全景•路演天下"网站（http://rs.p5w.net）参与公司本 次投资者集体接待日活动,时间为2020年8月21日（周五）15:30至17:00。 届时公司总经理薛晓民先生、董事会秘书丁富君先生、财务总监毕建涛先生， 将通过网络在线问答互动的形式，与投资者就公司治理、发展经营情况和可持续 发展等投资者关注的问题进行交流。期间，公司高管将全程在线，实时回答投资 者的提问。 欢迎广大投资者积极参与。 特此公告。 吉 ...

Financial Performance - The company's operating revenue for the first half of 2020 was ¥396,894,638.67, a decrease of 21.45% compared to ¥505,302,444.58 in the same period last year[18]. - The net profit attributable to shareholders was ¥32,843,900.69, down 18.00% from ¥40,051,961.83 in the previous year[18]. - The net cash flow from operating activities was ¥39,709,022.32, representing a significant decline of 66.98% compared to ¥120,240,092.59 in the same period last year[18]. - The basic earnings per share decreased to ¥0.0992, down 18.02% from ¥0.1210 in the previous year[18]. - Total operating revenue for the reporting period was 396.89 million yuan, a decline of 21.45% from 505.30 million yuan in the previous year, primarily due to the impact of the pandemic on sales[38]. - Operating costs decreased by 21.58% to 90.64 million yuan, reflecting the reduction in sales revenue[38]. - Sales expenses fell by 24.85% to 196.89 million yuan, attributed to reduced marketing expenditures during the pandemic[39]. - The cosmetics segment reported a sales revenue of 87.62 million yuan, a decrease of 34.61% compared to the same period last year, with a net profit of 15.54 million yuan, down 53.79% year-on-year[36]. - The pharmaceutical sector accounted for 77.72% of total revenue, generating 308.48 million yuan, down 13.98% year-on-year[41]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,490,038,186.79, a slight decrease of 0.26% from ¥2,496,513,671.23 at the end of the previous year[18]. - The net assets attributable to shareholders increased by 0.84% to ¥1,948,501,752.52 from ¥1,932,205,431.83 at the end of the previous year[18]. - Total liabilities decreased to CNY 409,756,074.33 from CNY 438,662,072.17, a reduction of about 6.6%[116]. - The company's total assets amounted to CNY 2,484,496,781.31, slightly down from CNY 2,505,218,983.50 at the end of 2019[121]. Cash Flow - The cash flow from operating activities dropped significantly by 66.98% to 39.71 million yuan, mainly due to reduced cash receipts from sales[39]. - The net increase in cash and cash equivalents was 7.52 million yuan, a decrease of 76.03% compared to the previous year, influenced by reduced cash receipts and increased dividend distributions[39]. - Cash inflow from financing activities was CNY 355,000,000.00, an increase of 47.9% compared to CNY 240,000,000.00 in the previous year[133]. - The total cash inflow from operating activities was CNY 449,205,355.95, a decrease of 25.5% compared to CNY 603,849,740.79 in the same period last year[132]. Research and Development - Research and development investment was 15.31 million yuan, a decrease of 7.87% compared to the previous year[39]. - The company has implemented a market-oriented R&D mechanism, collaborating with several top hospitals and universities to innovate and develop new products[30]. - The company obtained 4 invention patents during the reporting period, including 2 related to cosmetics and 2 related to pharmaceuticals[35]. Operational Risks and Challenges - The company faces various operational risks, which are detailed in the report[5]. - The company faced risks including production cost increases, drug price declines, and inventory devaluation due to market price uncertainties[59][60]. - The cosmetics industry saw a revenue decline of 36.59%, significantly impacted by the offline sales model affected by COVID-19[43]. Corporate Governance and Compliance - The half-year financial report has not been audited[66]. - The company did not engage in any major related party transactions, including asset acquisitions or disposals, during the reporting period[74][75][76][77][78]. - The company has not faced any bankruptcy restructuring matters during the reporting period[68]. - The company confirms its ability to continue as a going concern for at least 12 months from the reporting date[152]. Shareholder Information - The total number of shares outstanding remained at 330,951,600, with 29.98% being limited shares and 70.02% being unrestricted shares[93]. - Zhang Yisheng holds 39.08% of the shares, totaling 129,348,530 shares[96]. - Liu Jianming's shareholding decreased by 310,000 shares, now holding 4.21%[96]. - Zhao Wei increased his holdings by 1,520,000 shares, now holding 1.37%[96]. Environmental and Social Responsibility - The company maintained a strong commitment to environmental protection, adhering to relevant laws and regulations, with no significant pollution incidents or administrative penalties during the reporting period[87]. - The company has established a comprehensive emergency response mechanism for environmental pollution incidents[87]. - The company did not conduct any significant charitable activities or poverty alleviation initiatives during the reporting period[88]. Future Outlook - Future outlook and performance guidance were not explicitly provided in the documents, highlighting a need for further strategic communication[143]. - The company is focusing on improving cash flow management and exploring new investment opportunities to enhance financial stability[136].

Financial Performance - The company's revenue for Q1 2020 was CNY 200,410,031.97, a decrease of 18.10% compared to CNY 244,687,559.79 in the same period last year[9] - Net profit attributable to shareholders was CNY 21,483,641.33, an increase of 27.34% from CNY 16,871,558.99 year-on-year[9] - Basic earnings per share rose to CNY 0.0649, reflecting a growth of 27.25% compared to CNY 0.0510 in the same quarter last year[9] - The company's operating profit for Q1 2020 was CNY 31,513,381.89, an increase of 35% compared to CNY 23,355,685.80 in the same period last year[41] - Total profit for Q1 2020 reached CNY 29,813,960.90, up from CNY 22,831,521.01, reflecting a growth of 30% year-over-year[41] - The company reported a total comprehensive income of CNY 25,202,056.45 for Q1 2020, compared to CNY 19,746,399.38 in the same period last year, an increase of 28%[42] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 56.00% to CNY 31,724,684.07 from CNY 72,102,073.45 in the previous year[9] - Cash and cash equivalents increased by 40.85% to ¥88,753,739.80 from ¥63,014,615.13 due to higher net cash inflows from operating activities[19] - The company reported a significant decrease in cash received from operating activities, with a drop of 65.62% in other operating cash receipts to ¥7,445,649.18 from ¥21,655,390.40[19] - The net cash flow from operating activities was 31,724,684.07 CNY, a decrease of 56.1% compared to 72,102,073.45 CNY in the previous period[49] - The company incurred cash outflows of 204,418,446.85 CNY from operating activities, slightly down from 209,259,082.96 CNY in the previous period[49] - Cash inflows from financing activities were 110,000,000.00 CNY, compared to 200,000,000.00 CNY in the previous period, indicating a 45% decrease[50] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,503,032,462.36, a slight increase of 0.26% from CNY 2,496,513,671.23 at the end of the previous year[9] - Total liabilities decreased to CNY 419,978,806.85 from CNY 438,662,072.17, a decline of about 4.5%[34] - Total assets amounted to 2,505,218,983.50, with current assets at 1,729,611,557.12 and non-current assets at 775,607,426.38[58] - Total liabilities reached 604,212,756.22, with current liabilities at 569,177,496.77 and non-current liabilities at 35,035,259.45[59] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,737[13] - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, totaling 129,348,530 shares[13] - The net assets attributable to shareholders increased by 1.11% to CNY 1,953,689,073.16 from CNY 1,932,205,431.83 at the end of the previous year[9] - Total equity attributable to shareholders increased to CNY 1,953,689,073.16 from CNY 1,932,205,431.83, reflecting a growth of approximately 1.1%[34] Operating Costs and Expenses - Total operating costs for Q1 2020 were CNY 174,222,202.57, down from CNY 220,037,363.00 in the previous period[40] - The company reported a decrease in sales expenses to CNY 95,951,134.28 from CNY 125,561,248.13, a reduction of about 23.6%[40] - Research and development expenses increased to CNY 4,295,439.68 from CNY 3,451,674.58, representing an increase of approximately 24.5%[40] Government Subsidies - The company received government subsidies amounting to CNY 7,628,672.34 during the reporting period[10] - Other income surged by 393.79% to ¥7,741,091.20 from ¥1,567,689.64, primarily due to an increase in government subsidies received[19] Miscellaneous - The company has not undergone an audit for the first quarter report[60] - The company is implementing new revenue and lease standards starting in 2020, with no retrospective adjustments required[60] - The chairman of the company is Zhang Yisheng, indicating leadership continuity[61]

Financial Performance - The company's operating revenue for 2019 was CNY 1,012,748,483.99, representing a 3.86% increase compared to CNY 975,088,200.72 in 2018[17] - The net profit attributable to shareholders for 2019 was CNY 76,598,736.73, which is a 10.89% increase from CNY 69,079,282.05 in 2018[17] - The net profit after deducting non-recurring gains and losses was CNY 63,736,372.05, up 11.95% from CNY 56,934,533.88 in the previous year[17] - The net cash flow from operating activities increased by 26.03% to CNY 210,871,994.83, compared to CNY 167,318,427.92 in 2018[17] - The basic earnings per share for 2019 was CNY 0.2314, reflecting a 10.88% increase from CNY 0.2087 in 2018[17] - Total assets at the end of 2019 were CNY 2,496,513,671.23, a decrease of 2.22% from CNY 2,553,101,177.99 at the end of 2018[17] - The net assets attributable to shareholders increased by 4.13% to CNY 1,932,205,431.83, compared to CNY 1,855,606,695.10 at the end of 2018[17] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of CNY 0.5 per 10 shares, based on a total of 330,951,600 shares[6] - The cash dividend for 2019 represents 21.60% of the net profit attributable to shareholders, which was RMB 76,598,736.73[87] - The company maintained a cash dividend payout ratio of 100% for the 2019 fiscal year[88] - The total distributable profit available to shareholders as of December 31, 2019, was RMB 634,529,034.45, after accounting for statutory reserves[88] Risks and Challenges - The company faces potential risks including industry policy adjustments, rising production costs, and talent shortages[6] - The company faces risks related to industry policy adjustments, rising production costs, and potential price declines for pharmaceuticals[76] Product Development and Market Strategy - The company completed the research and development of 12 new products, including collagen peptide drinks and red ginseng pomegranate juice, during the reporting period[38] - The company is actively exploring market opportunities and enhancing its product competitiveness through academic promotion and market demand analysis[28] - The company has diversified its product offerings to include traditional Chinese medicine, health products, and cosmetics, positioning itself as a comprehensive health enterprise[26] - The company is focused on product development based on market demand, aiming to enhance competitiveness in the ginseng industry[75] Sales and Revenue Segments - Sales revenue from the health food segment was CNY 7,714.89 million, a decline of 27.19% year-on-year[38] - The traditional Chinese medicine segment generated sales revenue of CNY 1,778.75 million, an increase of 214.28% compared to the previous year[39] - The cosmetics segment achieved sales revenue of CNY 263.67 million, a year-on-year increase of 10.20%, with a net profit of CNY 41.35 million, down 3.90% from the previous year[40] - The cosmetics industry contributed CNY 186.67 million to total revenue, a significant increase of 37.99% from CNY 135.28 million in the previous year[44] Governance and Compliance - The company has established a governance structure to protect the rights of shareholders and creditors, ensuring compliance with relevant laws and regulations[117] - The company has established a complete governance structure that complies with relevant laws and regulations, enhancing governance levels[165] - The company has implemented a performance evaluation system linking employee salaries to company performance and individual work results[161] Social Responsibility and Sustainability - The company emphasizes its commitment to social responsibility and sustainable development, focusing on economic benefits while protecting stakeholder interests[116] - The company has maintained compliance with environmental protection regulations, with no major pollution incidents or administrative penalties reported during the reporting period[121] - The company actively participates in social welfare activities, fulfilling its social responsibilities by caring for vulnerable groups and contributing to charitable causes[119] Shareholder Information - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, totaling 129,348,530 shares[132] - The total number of shares remained unchanged at 330,951,600, with limited sale condition shares decreasing from 103,192,171 (31.18%) to 99,231,016 (29.98%) and unrestricted shares increasing from 227,759,429 (68.82%) to 231,720,584 (70.02%) [128] - The total number of shareholders at the end of the reporting period was 21,926, with no significant changes reported[131] Internal Controls and Audit - The audit report issued by Zhongzhun Zhonghuan Accounting Firm provided a standard unqualified opinion on the financial statements[187] - The management assessed the net realizable value of inventory based on market fair value and estimated costs, which is crucial for impairment testing[190] - No significant internal control deficiencies were reported during the period[181] Employee and Management Information - The total number of employees in the company is 1,816, with 1,499 in the parent company and 317 in major subsidiaries[159] - The company has established a performance evaluation system for directors and senior management, linking their remuneration to company performance[157] - The educational background of employees shows 310 with a degree above bachelor's, 402 with a college diploma, and 1,104 below college level[159]

Financial Performance - Operating revenue for the reporting period was CNY 240,548,305.91, representing a year-on-year increase of 6.16%[7] - Net profit attributable to shareholders of the listed company was CNY 15,261,150.82, up 10.21% year-on-year[7] - Basic earnings per share for the reporting period were CNY 0.0461, an increase of 10.29% compared to the same period last year[7] - Total operating revenue for the current period reached ¥240,548,305.91, an increase of 6.9% compared to ¥226,591,334.39 in the previous period[38] - Total operating costs amounted to ¥218,189,592.71, up from ¥206,650,280.90, reflecting a rise of 5.8%[38] - Operating profit decreased to ¥18,543,599.22 from ¥20,419,563.27, a decline of 9.2%[39] - Net profit for the current period was ¥15,131,185.24, down 8.7% from ¥16,584,006.69 in the previous period[39] - The net profit attributable to the parent company was CNY 55,313,112.65, an increase from CNY 53,129,794.87, showing a growth of approximately 4.1%[48] - Basic and diluted earnings per share were both CNY 0.1671, up from CNY 0.1605 in the previous period, representing an increase of about 4.1%[48] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,540,074,543.43, a decrease of 0.51% compared to the end of the previous year[7] - Total current assets amounted to CNY 2,020,811,110.30, slightly up from CNY 2,014,562,591.55 in the previous period[29] - Total non-current assets decreased to CNY 519,263,433.13 from CNY 538,538,586.44, with fixed assets at CNY 414,493,453.93, down from CNY 437,564,163.19[29] - Total liabilities decreased to CNY 506,246,163.32 from CNY 587,494,366.01, with current liabilities at CNY 459,077,665.38, down from CNY 542,215,902.60[30] - Owner's equity increased to CNY 2,033,828,380.11 from CNY 1,965,606,811.98, with retained earnings rising to CNY 645,149,564.50 from CNY 589,836,451.85[31] - Short-term borrowings decreased to CNY 350,000,000.00 from CNY 430,000,000.00, indicating a reduction in debt[34] - Long-term borrowings increased to CNY 13,020,000.00 from CNY 10,470,000.00, suggesting a strategic move to finance long-term projects[35] Cash Flow - Net cash flow from operating activities decreased significantly by 69.99% to CNY 8,406,884.56[7] - Operating cash flow increased by 39.26% to ¥128,646,977.15 from ¥92,381,953.78, mainly due to reduced purchasing expenses[19] - The cash flow from operating activities was CNY 841,840,854.43, compared to CNY 838,704,254.90 in the previous period, showing a slight increase[54] - The total cash inflow from operating activities increased to ¥701,293,856.49 from ¥670,703,586.11 year-on-year[59] - The company reported a net cash outflow from investing activities of ¥15,296,426.17, compared to a net outflow of ¥43,365,425.14 in the same period last year[56] - Cash inflow from financing activities was ¥322,550,000.00, while cash outflow was ¥413,388,686.33, leading to a net cash outflow of ¥90,838,686.33[56] Shareholder Information - The company reported a total of 21,915 common shareholders at the end of the reporting period[11] - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, totaling 129,348,530 shares[11] - The company plans to address the issue of shareholding representation by reducing the shares held by certain shareholders in a manner that minimizes market impact[14] - The company aims to resolve the shareholding representation issue promptly while protecting the interests of minority investors[14] Government Subsidies and Expenses - The company received government subsidies amounting to CNY 6,485,858.51 during the reporting period[8] - Research and development expenses rose to ¥7,187,456.00, an increase of 11.3% compared to ¥6,455,227.73[38] - Sales expenses increased to ¥128,943,551.63, up 5.3% from ¥121,771,529.54[38] - Tax expenses increased significantly to ¥4,259,740.01 from ¥2,585,892.18, a rise of 64.7%[38] - The company reported a credit impairment loss of ¥6,292,297.70, indicating potential challenges in asset quality[39] - Tax expenses for the period were CNY 12,332,735.80, slightly down from CNY 12,530,169.57, indicating a decrease of about 1.6%[47] Inventory and Receivables - Cash and cash equivalents increased to CNY 33,395,694.64 from CNY 28,207,006.00, while accounts receivable rose to CNY 194,061,234.95 from CNY 173,942,860.37[33] - Inventory levels remained stable at CNY 1,387,558,592.18, compared to CNY 1,376,696,766.62 in the previous period[33] - Prepayments rose by 112.35% to ¥40,815,469.60 from ¥19,220,882.94, primarily due to increased advance payments for Han Shen cosmetics[19]

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 505,302,444.58, a decrease of 3.47% compared to the same period last year[17]. - The net profit attributable to shareholders was CNY 40,051,961.83, representing a year-on-year increase of 1.96%[17]. - The net cash flow from operating activities increased significantly by 86.79%, reaching CNY 120,240,092.59[17]. - The total revenue for the first half of 2019 was CNY 577,325,748.23, a decrease from CNY 593,496,330.04 in the same period of 2018, representing a decline of approximately 2.0%[124]. - The net profit for the first half of 2019 was CNY 21,632,178.28, down from CNY 23,504,694.31 in the first half of 2018, indicating a decrease of about 7.9%[123]. - The total operating costs decreased to CNY 447,556,288.64, down 3.0% from CNY 461,446,709.69 year-on-year[117]. - The company reported a total share count of 330,951,600, with no changes during the reporting period[84]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,529,410,810.99, a decrease of 0.93% from the end of the previous year[17]. - The company's total liabilities decreased to CNY 510,713,616.12 from CNY 587,494,366.01, a decline of about 13.1%[110]. - Short-term borrowings decreased to CNY 360 million, down from CNY 490 million, primarily due to repayment of bank loans[44]. - The company's equity increased to CNY 2,018,697,194.87 from CNY 1,965,606,811.98, an increase of approximately 2.4%[110]. - The company's current assets totaled CNY 2,006,046,508.65, slightly down from CNY 2,014,562,591.55 at the end of 2018[108]. Revenue by Segment - Sales revenue for the flagship product Zhenyuan Capsule reached CNY 182.01 million, growing by 1.70% year-on-year[33]. - Sales revenue for Xinyue Capsule was CNY 46.62 million, an increase of 7.46% compared to the previous year[33]. - Sales revenue for Xiaozhilin Injection reached CNY 34.07 million, marking a significant growth of 36% year-on-year[33]. - The sales revenue from the health food segment dropped significantly by 49.04%, amounting to RMB 34.47 million, primarily due to a substantial decline in trade food income[38]. - The Chinese herbal medicine segment achieved sales revenue of RMB 8.43 million, reflecting a growth of 48.98% year-on-year[34]. - The cosmetics business generated sales revenue of RMB 133.99 million, a decrease of 7.87% compared to the previous year, while net profit increased by 1.43% to RMB 33.64 million[34]. Research and Development - Research and development expenses decreased by 24.79% to RMB 16.62 million, indicating a reduction in investment in new product development[36]. - The company completed the research and filing of seven new products, including red ginseng pomegranate juice and ginseng fermented fruit and vegetable drinks[33]. Cash Flow - The cash flow from operating activities for the first half of 2019 was CNY 120,240,092.59, an increase from CNY 64,372,694.33 in the same period of 2018, reflecting a growth of approximately 86.8%[126]. - The cash flow from investing activities showed a net outflow of CNY 9,458,198.78 in the first half of 2019, compared to a net outflow of CNY 41,056,657.35 in the same period of 2018, indicating an improvement in cash flow management[126]. - The cash flow from financing activities resulted in a net outflow of CNY 79,424,594.96 in the first half of 2019, compared to a net outflow of CNY 70,079,828.87 in the same period of 2018[127]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 23,075[89]. - Zhang Yisheng holds 39.08% of the shares, totaling 129,348,530 shares[89]. - Liu Jianming holds 5.56% of the shares, totaling 18,393,303 shares[89]. - Zhao Wei holds 1.13% of the shares, totaling 3,730,300 shares[89]. - The proportion of restricted shares decreased from 31.18% to 30.75%, while unrestricted shares increased from 68.82% to 69.25%[85]. Corporate Governance - The financial report was approved by the board on August 23, 2019[145]. - The company adheres to the accounting standards and ensures the financial statements reflect a true and complete picture of its financial status[149]. - The company has not engaged in any major related party transactions during the reporting period[69]. - The company has not reported any significant changes in its management personnel or compensation during the reporting period[81]. Environmental and Social Responsibility - There were no significant environmental pollution incidents or administrative penalties related to environmental issues during the reporting period[79]. - The company has established a comprehensive emergency response mechanism for environmental pollution incidents[79]. - The company has not initiated any poverty alleviation programs during the reporting period and has no plans for future initiatives[80]. Future Outlook - The company has not provided specific guidance on future performance or new product developments in the available reports[126].